Artificial Intelligence

At a key industry summit, Sutro Biopharma showcases its next-gen ADC platform, designed to overcome treatment resistance with "supercharged" dual-payload drugs.

As Lyell presents at three major investor conferences, the biotech's pipeline, financial health, and future in cancer therapy are under scrutiny.

A Malaysian biotech's new study shows its NK cell therapy is safe, using a novel, low-cost method that could make advanced cancer treatment affordable worldwide.

Facing financial headwinds, network supplier DAVOLINK is merging with LoadRunner, pivoting to the booming but brutal AI-driven industrial automation market.

An international initiative uniting a Japanese firm, the UN, and Aikido masters empowers Los Angeles women with non-violent self-defense techniques.

AI firm DreamzTech Solutions gains major recognition, validating its AI-first strategy and signaling a new wave of Indian tech leaders on the global stage.

A brief delay in Avidity's stockholder vote signals the final, complex steps before its acquisition by Novartis and the launch of a new spin-off.

Pure Storage rebrands as Everpure and acquires 1touch, betting its future on providing the intelligent data management layer essential for enterprise AI.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

iRegene Therapeutics hits dual milestones, advancing AI-derived cell therapies for Parkinson's in the US and Multiple System Atrophy in China.

January data shows a massive jump in corporate financing requests, hinting at a busy year for investment, while the municipal market tells a different story.

Light Source Communications is building a massive underground dark fiber network to connect St. Louis and Tulsa, powering the AI revolution in the heartland.

A new initiative offers biotech firms free access to advanced epiproteomic analysis, aiming to accelerate the development of next-generation precision medicines.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

New 12- and 24-month data for Benitec Biopharma's BB-301 gene therapy offers renewed hope for patients with a rare, debilitating muscular dystrophy.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

With revenue growth tied to shrinking margins, illumin's upcoming 2025 earnings report is a critical test of its strategy in a shifting ad tech world.

Armed with $320M in new capital, Anteris will showcase its revolutionary biomimetic heart valve to top investors. Can it disrupt a market of giants?